New insights into pattern recognition receptors and their ligands in gynecologic pathologies

Human Immunology

Volumn 72, Issue 3, 2011, Pages 213-218

  Yamada, Yoshihiko ^a   Shigetomi, Hiroshi ^a   Onogi, Akira ^a   Haruta, Shoji ^a   Kawaguchi, Ryuji ^a   Yoshida, Shozo ^a   Furukawa, Naoto ^a   Nagai, Akira ^a   Tanase, Yasuhito ^a   Tsunemi, Taihei ^a   Oi, Hidekazu ^a   Kobayashi, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Endometriosis; Hepatocyte nuclear factor 1 ; Ovarian cancer; Pattern recognition receptors

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HEPATOCYTE NUCLEAR FACTOR 1BETA; HIGH MOBILITY GROUP B1 PROTEIN; INSULIN RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; LIGAND; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; PATTERN RECOGNITION RECEPTOR; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; X LINKED INHIBITOR OF APOPTOSIS;

CARCINOGENESIS; CHROMOSOMAL INSTABILITY; CHRONIC INFLAMMATION; CLEAR CELL CARCINOMA; DISEASE ASSOCIATION; ENDOMETRIOID CARCINOMA; ENDOMETRIOSIS; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; INFLAMMATION; INNATE IMMUNITY; OVARY CANCER; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

CHROMOSOMAL INSTABILITY; ENDOMETRIOSIS; FEMALE; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HUMANS; IMMUNITY, INNATE; IRON; LIGANDS; OVARIAN NEOPLASMS; OXIDATIVE STRESS; RECEPTORS, PATTERN RECOGNITION;

EID: 79651472043     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2010.12.009     Document Type: Review

References (82)

1. Nasu K., Narahara H. Pattern recognition via the Toll-like receptor system in the human female genital tract. Mediat Inflamm 2010, 976024.
2. Bianchi M.E. PAMPs and alarmins: All we need to know about danger. J Leukoc Biol 2007, 81:1-5. DAMPs.
3. Chiron D., Bekeredjian-Ding I., Pellat-Deceunynck C., Bataille R., Jego G. Toll-like receptors: Lessons to learn from normal and malignant human B cells. Blood 2008, 112:2205-2213.
4. Lotze M.T., Zeh H.J., Rubartelli A., Sparvero L.J., Amoscato A.A., Washburn N.R., et al. The grateful dead: Damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 2007, 220:60-81.
5. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001, 108:949-955.
6. Chavakis T., Bierhaus A., Al-Fakhri N., Schneider D., Witte S., Linn T., et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: A novel pathway for inflammatory cell recruitment. J Exp Med 2003, 198. 1507-1.
7. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
8. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
9. Rakoff-Nahoum S., Medzhitov R. Role of Toll-like receptors in tissue repair and tumorigenesis. Biochemistry (Mosc) 2008, 73:555-561.
10. Son D.S., Parl A.K., Rice V.M., Khabele D. Keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) chemokines and pro-inflammatory chemokine networks in mouse and human ovarian epithelial cancer cells. Cancer Biol Ther 2007, 6:1302-1312.
11. Ikebe M., Kitaura Y., Nakamura M., Tanaka H., Yamasaki A., Nagai S., et al. Lipopolysaccharide (LPS) increases the invasive ability of pancreatic cancer cells through the TLR4/MyD88 signaling pathway. J Surg Oncol 2009, 100:725-731.
12. Chen R., Alvero A.B., Silasi D.A., Mor G. Inflammation, cancer and chemoresistance: Taking advantage of the Toll-like receptor signaling pathway. Am J Reprod Immunol 2007, 57:93-107.
13. Fukata M., Chen A., Klepper A., Krishnareddy S., Vamadevan A.S., Thomas L.S., et al. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology 2006, 131:862-877.
14. Oda K., Kitano H. A comprehensive map of the Toll-like receptor signaling network. Mol Syst Biol 2006, 2:0015.
15. Khan K.N., Kitajima M., Hiraki K., Yamaguchi N., Katamine S., Matsuyama T., et al. Escherichia coli contamination of menstrual blood and effect of bacterial endotoxin on endometriosis. Fertil Steril 2010, 94:2860-2863.
16. Khan K.N., Kitajima M., Hiraki K., Fujishita A., Sekine I., Ishimaru T., Masuzaki H. Toll-like receptors in innate immunity: Role of bacterial endotoxin and Toll-like receptor 4 in endometrium and endometriosis. Gynecol Obstet Invest 2009, 68:40-52.
17. Kobayashi H., Sumimoto K., Moniwa N., Imai M., Takakura K., Kuromaki T., et al. Risk of developing ovarian cancer among women with ovarian endometrioma: A cohort study in Shizuoka, Japan. Int J Gynecol Cancer 2007, 17:37-43.
18. Mandai M., Yamaguchi K., Matsumura N., Baba T., Konishi I. Ovarian cancer in endometriosis: Molecular biology, pathology, and clinical management. Int J Clin Oncol 2009, 14:383-391.
19. Dinulescu D.M., Ince T.A., Quade B.J., Shafer S.A., Crowley D., Jacks T. Role of K-ras and PTEN in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005, 11:63-70.
20. Wiegand K.C., Shah S.P., Al-Agha O.M., Zhao Y., Tse K., Zeng T., et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010, 363:1532-1543.
21. Jones S., Wang T.L., Shih IeM., Mao T.L., Nakayama K., Roden R., et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010, 330:228-231.
22. Kobayashi H., Yamada Y., Kanayama S., Furukawa N., Noguchi T., Haruta S., et al. The role of hepatocyte nuclear factor-1β in the pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol Cancer 2009, 19:471-479.
23. Kobayashi H., Sumimoto K., Kitanaka T., Yamada Y., Sado T., Sakata M., et al. Ovarian endometrioma-risks factors of ovarian cancer development. Eur J Obstet Gynecol Reprod Biol 2008, 138:187-193.
24. Hart K.M., Murphy A.J., Barrett K.T., Wira C.R., Guyre P.M., Pioli P.A. Functional expression of pattern recognition receptors in tissues of the human female reproductive tract. J Reprod Immunol 2009, 80:33-40.
25. Diamanti-Kandarakis E., Piperi C., Patsouris E., Korkolopoulou P., Panidis D., Pawelczyk L., et al. Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol 2007, 127:581-589.
26. Dubicke A., Andersson P., Fransson E., Andersson E., Sioutas A., Malmström A., et al. High-mobility group box protein 1 and its signalling receptors in human preterm and term cervix. J Reprod Immunol 2010, 84:86-94.
27. Cooke C.L., Brockelsby J.C., Baker P.N., Davidge S.T. The receptor for advanced glycation end products (RAGE) is elevated in women with preeclampsia. Hypertens Pregnancy 2003, 22:173-184.
28. Kobayashi H. Ovarian cancer in endometriosis: Epidemiology, natural history, and clinical diagnosis. Int J Clin Oncol 2009, 14:378-382.
29. Kobayashi H., Kajiwara H., Kanayama S., Yamada Y., Furukawa N., Noguchi T., et al. Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary. Oncol Rep 2009, 22:233-240.
30. Sharma I., Dhawan V., Saha S.C., Rashmi B., Dhaliwal L.K. Implication of the rage-EN-RAGE axis in endometriosis. Int J Gynecol Obstet 2010, 110:199-202.
31. Rier S.E., Yeaman G.R. Immune aspects of endometriosis: Relevance of the uterine mucosal immune system. Semin Reprod Endocrinol 1997, 15:209-220.
32. Kligman I., Jeremias J., Rosenwaks Z., Witkin S.S. Cell-mediated immunity to human and Escherichia coli 60-kDa heat shock protein in women: Association with a history of spontaneous abortion and endometriosis. Am J Reprod Immunol 1998, 40:32-36.
33. Kajihara H., Yamada Y., Kanayama S., Furukawa N., Noguchi T., Haruta S., et al. New insights into the pathophysiology of endometriosis: From chronic inflammation to danger signal. Gynecol Endocrinol 2010.
34. Murphy A.A., Santanam N., Endometriosis P.S. A disease of oxidative stress?. Semin Reprod Endocrinol 1998, 16:263-273.
35. Sato Y., Goto Y., Narita N., Hoon D.S. Cancer cells expressing Toll-like receptors and the tumor microenvironment. Cancer Microenviron 2009, 2:205-214.
36. O'Callaghan G., Kelly J., Shanahan F., Houston A. Prostaglandin E-2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells. Br J Cancer 2008, 99:502-512.
37. Hernandez Y., Sotolongo J., Breglio K., Conduah D., Chen A., Xu R., et al. The role of prostaglandin E2 (PGE 2) in Toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia. BMC Gastroenterol 2010, 10:82.
38. Chen K., Huang J., Gong W., Iribarren P., Dunlop N.M., Wang J.M. Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol 2007, 7:1271-1285.
39. Markovic D.S., Vinnakota K., Chirasani S., Synowitz M., Raguet H., Stock K., et al. Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc Natl Acad Sci U S A 2009, 106:12530-12535.
40. Yang H., Zhou H., Feng P., Zhou X., Wen H., Xie X., et al. Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res 2010, 29:92.
41. Alvero A.B., Chen R., Fu H.H., Montagna M., Schwartz P.E., Rutherford T., et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009, 8:158-166.
42. Kelly M.G., Alvero A.B., Chen R., Silasi D.A., Abrahams V.M., Chan S., et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006, 66:3859-3868.
43. Huang B., Zhao J., Li H., He K.L., Chen Y., Chen S.H., et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005, 65:5009-5014.
44. Liu G., Zhao Y. Toll-like receptors and immune regulation: Their direct and indirect modulation on regulatory CD4+ CD25+ T cells. Immunology 2007, 122:149-156.
45. Klune J.R., Dhupar R., Cardinal J., Billiar T.R., Tsung A. HMGB1: Endogenous danger signaling. Mol Med 2008, 14:476-484.
46. Curtin J.F., Liu N., Candolfi M., Xiong W., Assi H., Yagiz K., et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med 2009, 6:e10.
47. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-1059.
48. Jasani B., Navabi H., Adams M. Ampligen: A potential Toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 2009, 27:3401-3404.
49. Killeen S.D., Wang J.H., Andrews E.J., Redmond H.P. Exploitation of the Toll-like receptor system in cancer: A doubled-edged sword?. Br J Cancer 2006, 95:247-252.
50. Taguchi A., Blood D.C., del Toro G., Canet A., Lee D.C., Qu W., et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000, 405:354-360.
51. Ang C.W., Nedjadi T., Sheikh A.A., Tweedle E.M., Tonack S., Honap S., et al. Smad4 loss is associated with fewer S100A8-positive monocytes in colorectal tumors and attenuated response to S100A8 in colorectal and pancreatic cancer cells. Carcinogenesis 2010, 31:1541-1551.
52. Berger R., Fiegl H., Goebel G., Obexer P., Ausserlechner M., Doppler W., et al. Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci 2010, 101:1059-1066.
53. Szajnik M., Szczepanski M.J., Czystowska M., Elishaev E., Mandapathil M., Nowak-Markwitz E., et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene 2009, 28:4353-4363.
54. Dan H.C., Sun M., Kaneko S., Feldman R.I., Nicosia S.V., Wang H.G., et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004, 279:5405-5412.
55. Agarwal R., Whang D.H., Alvero A.B., Visintin I., Lai Y., Segal E.A., et al. Macrophage migration inhibitory factor expression in ovarian cancer. Am J Obstet Gynecol 2007, 196:e1-e5.
56. Bach J.P., Deuster O., Balzer-Geldsetzer M., Meyer B., Dodel R., Bacher M. The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer 2009, 115:2031-2040.
57. Chuang C.M., Monie A., Wu A., Mao C.P., Hung C.F. Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum Gene Ther 2009, 20:303-313.
58. Kluwe J., Mencin A., Schwabe R.F. Toll-like receptors, wound healing, and carcinogenesis. J Mol Med 2009, 87:125-138.
59. Gurtsevitch V.E. Human oncogenic viruses: Hepatitis B and hepatitis C viruses and their role in hepatocarcinogenesis. Biochemistry (Mosc) 2008, 73:504-513.
60. Hong S., Lee H.J., Kim S.J., Hahm K.B. Connection between inflammation and carcinogenesis in gastrointestinal tract: Focus on TGF-β signaling. World J Gastroenterol 2010, 16:2080-2093.
61. Toyokuni S., Okamoto K., Yodoi J., Hiai H. Persistent oxidative stress in cancer. FEBS Lett 1995, 358:1-3.
62. Park S., Kim W.S., Choi U.J., Han S.U., Kim Y.S., Kim Y.B., et al. Amelioration of oxidative stress with ensuing inflammation contributes to chemoprevention of H pylori-associated gastric carcinogenesis. Antioxid Redox Signal 2004, 6:549-560.
63. Xiang M., Fan J., Fan J. Association of Toll-like receptor signaling and reactive oxygen species: A potential therapeutic target for posttrauma acute lung injury. Mediat Inflamm 2010, ii:916425.
64. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
65. Kuper H., Adami H.O., Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med 2000, 248:171-183.
66. Westbrook A.M., Szakmary A., Schiestl R.H. Mechanisms of intestinal inflammation and development of associated cancers: Lessons learned from mouse models. Mutat Res 2010, 705:40-59.
67. Yamaguchi K., Mandai M., Toyokuni S., Hamanishi J., Higuchi T., Takakura K., et al. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin Cancer Res 2008, 14:32-40.
68. Yamaguchi K., Mandai M., Oura T., Matsumura N., Hamanishi J., Baba T., et al. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 2010, 29:1741-1752.
69. Blokhina O., Virolainen E., Fagerstedt K.V. Antioxidants, oxidative damage and oxygen deprivation stress: A review. Ann Bot 2003, 91:179-194.
70. Kajihara H., Yamada Y., Kanayama S., Furukawa N., Noguchi T., Haruta S., et al. Clear cell carcinoma of the ovary: Potential pathogenic mechanisms. Oncol Rep 2010, 23:1193-1203.
71. Elstrand M.B., Kleinberg L., Kohn E.C., Tropé C.G., Davidson B. Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma. Int J Gynecol Pathol 2009, 28:211-221.
72. Ozturk A., Vieira A.R. TLR4 as a risk factor for periodontal disease: A reappraisal. J Clin Periodontol 2009, 36:279-286.
73. Itamochi H., Kigawa J., Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 2008, 99:653-658.
74. Pham T.N., Hong C.Y., Min J.J., Rhee J.H., Nguyen T.A., Park B.C., et al. Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist. Exp Mol Med 2010, 42:407-419.
75. Friedberg J.W., Kelly J.L., Neuberg D., Peterson D.R., Kutok J.L., Salloum R., et al. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol 2009, 146:282-291.
76. Stary G., Bangert C., Tauber M., Strohal R., Kopp T., Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 2007, 204:1441-1451.
77. Geller M.A., Cooley S., Argenta P.A., Downs L.S., Carson L.F., Judson P.L., et al. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol Immunother 2010, 59:1877-1884.
78. Spaner D.E., Shi Y., White D., Shaha S., He L., Masellis A., et al. A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia. Leukemia 2010, 24:222-226.
79. Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 2007, 13:1076-1082.
80. Mbonye U.R., Song I. Posttranscriptional and posttranslational determinants of cyclooxygenase expression. BMB Rep 2009, 42:552-560.
81. Half E., Arber N. Colon cancer: Preventive agents and the present status of chemoprevention. Expert Opin Pharmacother 2009, 10:211-219.
82. Kicic A., Chua A.C., Baker E. The desferrithiocin (DFT) class of iron chelators: Potential as antineoplastic agents. Anticancer Drugs Des 2001, 16:195-207.